Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02494882
Title Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Memorial Sloan Kettering Cancer Center
Indications
Therapies
Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
Memorial Sloan Kettering Cancer Center New York New York 10065 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field